LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company's segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products. Cardiac Surgery products include oxygenators, heart-lung machines, autotransfusion, mechanical heart valves and tissue heart valves. The Cardiac Rhythm Management segment is engaged in the development, manufacturing and marketing of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Cardiac Rhythm Management products include high-voltage defibrillators Cardiac Resynchronization Therapy device (CRT-D) and low-voltage pacemakers. The Neuromodulation segment is engaged in the design, development and marketing of neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment resistant depression.
Industry, Sector and Symbol
Stock Exchange LON
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolLON:LIVN
CUSIPN/A
Phone+44-20-37865275
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-8.31%
Return on Equity-1.00%
Return on Assets-1.25%
Miscellaneous
EmployeesN/A
Outstanding Shares48,180,000
Market Cap£0.00
LivaNova (LON:LIVN) Frequently Asked Questions
What is LivaNova's stock symbol?
LivaNova trades on the London Stock Exchange (LON) under the ticker symbol "LIVN."
Who are LivaNova's key executives?
LivaNova's management team includes the folowing people:
- Daniel Jeffrey Moore, Chairman of the Board
- Damien McDonald, Chief Executive Officer, Director
- Thad Allen Huston, Chief Financial Officer
- Douglas J. Manko, Chief Accounting Officer
- David S. Wise, Chief Administrative Officer
- Francesco Bianchi, Independent Director
- Stefano Gianotti, Independent Director
- Hugh M. Morrison, Independent Director
- Alfred J. Novak, Independent Director
- Sharon O'Kane Ph.D., Independent Director
Has LivaNova been receiving favorable news coverage?
Press coverage about LIVN stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. LivaNova earned a news and rumor sentiment score of 0.12 on Accern's scale. They also gave media headlines about the company an impact score of 47.35 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for LivaNova.
How do I buy shares of LivaNova?
Shares of LIVN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
How can I contact LivaNova?
LivaNova's mailing address is 20 Eastbourne Terrace, LONDON, W2 6LG, United Kingdom. The company can be reached via phone at +44-20-37865275.
MarketBeat Community Rating for LivaNova (LON LIVN)
MarketBeat's community ratings are surveys of what our community members think about LivaNova and other stocks. Vote "Outperform" if you believe LIVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LIVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
